Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
WALTHAM, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted […]